0001593968-20-000523.txt : 20200226 0001593968-20-000523.hdr.sgml : 20200226 20200226180152 ACCESSION NUMBER: 0001593968-20-000523 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200224 FILED AS OF DATE: 20200226 DATE AS OF CHANGE: 20200226 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Marguglio David J. CENTRAL INDEX KEY: 0001461753 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36242 FILM NUMBER: 20657603 MAIL ADDRESS: STREET 1: 2658 DEL MAR HEIGHTS RD., #555 CITY: DEL MAR STATE: CA ZIP: 92014 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adamis Pharmaceuticals Corp CENTRAL INDEX KEY: 0000887247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820429727 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11682 EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 997-2400 MAIL ADDRESS: STREET 1: 11682 EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: CELLEGY PHARMACEUTICALS INC DATE OF NAME CHANGE: 19950615 4 1 primary_01.xml PRIMARY DOCUMENT X0306 4 2020-02-24 0000887247 Adamis Pharmaceuticals Corp ADMP 0001461753 Marguglio David J. C/O ADAMIS PHARMACEUTICALS CORPORATION 11682 EL CAMINO REAL, STE 300 SAN DIEGO CA 92130- true true false false SVP and Chief Business Officer Common Stock 2020-02-24 4 S false 9948 0.6035 D 335359 D Common Stock 5884 I By D. Marguglio as custodian for children The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The shares were sold to satisfy the withholding and tax obligations relating to the issuance of shares upon the vesting of RSUs previously granted to the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.615 to $0.608, inclusive. The reporting person undertakes to provide Adamis Pharmaceuticals Corporation, any security holder of Adamis Pharmaceuticals Corporation, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. /s/Robert O. Hopkins, Power of Attorney for David J. Marguglio 2020-02-26